Clearance of genital warts in a pediatric patient following administration of the nonavalent human papillomavirus vaccine

Couselo-Rodríguez, Carmen; Pérez-Feal, Patricia; Alarcón-Pérez, Camilo E; Bou‐Boluda, Laia; Baselga, Eulàlia

doi:10.1111/ijd.15569

Cited by 4 publications

(4 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The therapeutic efficacy of the last commercialized 9vHPV vaccine on AGWs was assessed only recently in three small case series [32] and in two case reports [33,34] as well as in the present report.…”

Section: Discussionmentioning

confidence: 72%

See 1 more Smart Citation

Efficacy of Human Papillomavirus Vaccines for Recalcitrant Anogenital and Oral Warts

Ciccarese,

Herzum,

Serviddio

et al. 2023

JCM

View full text Add to dashboard Cite

Human papillomavirus (HPV) vaccines are preventive measures to decrease HPV infection rates. Knowledge of their efficacy as treatment options for anogenital warts (AGWs) and oral warts (OWs) is limited. To evaluate the efficacy of HPV vaccinations in recalcitrant AGWs and OWs (lesions persisting more than 6 months despite conventional treatments), we compared a group of patients treated with standard therapies plus an HPV vaccine with a group of patients treated with standard therapies only. The response to treatment (in terms of the number of lesions) in the two groups was compared. Data were analyzed with the χ2 test and p values < 0.05 were considered to be statistically significant. The study included 14 patients (group A = cases) who received 3 doses of an intramuscular HPV vaccine (Gardasil 4 or Gardasil 9) in addition to the standard treatments for AGWs and OWs, and 15 age- and sex-matched patients (group B = controls) with an analogous number of lesions to group A who received only standard therapies. After 12 months, 85% of patients of group A versus 33% of group B had positive clinical outcomes (0.004). Our findings suggest a possible therapeutic role of HPV vaccines in addition to standard treatments for AGWs/OWs. Preventive vaccines, blocking the viral entry through the induction of L1-specific antibodies, can prevent autologous reinfections (through auto-inoculation) and favor the elimination of the virus.

show abstract

Section: Discussionmentioning

confidence: 72%

“…However, to date, only a few studies and sporadic case reports have focused on the possible therapeutic role of HPV vaccines (both the 2vHPVvaccine and 4vHPV vaccine); these obtained partly contradictory results [27][28][29][30][31][32][33][34][35].…”

Section: Discussionmentioning

confidence: 99%

Efficacy of Human Papillomavirus Vaccines for Recalcitrant Anogenital and Oral Warts

Ciccarese,

Herzum,

Serviddio

et al. 2023

JCM

View full text Add to dashboard Cite

show abstract

“…Interestingly, despite a subgroup of three patients having previously received the qHPV vaccine, the clinical outcomes did not show a statistically significant difference when compared to individuals exclusively administered the 9vHPV vaccine in the study ( p > 0.05) [ 9 ]. Moreover, the 9vHPV vaccine demonstrated noteworthy outcomes in the treatment of young patients with both genital and extragenital warts following the administration of two doses [ 10 , 19 ]. Remarkably, a patient who received only one dose of the 9vHPV vaccine due to side effects demonstrated a significant reduction in the size of condylomas, with complete disappearance noted 1.5 years after the initial visit [ 20 ].…”

Section: Resultsmentioning

confidence: 99%

Unveiling the Therapeutic Horizon: HPV Vaccines and Their Impact on Cutaneous Diseases—A Comprehensive Review

Șandru,

Radu,

Petca

et al. 2024

Vaccines

View full text Add to dashboard Cite

Human papillomavirus (HPV) encompasses a diverse array of viruses, comprising approximately 200 serotypes that affect humans. While the majority of HPV strains are associated with benign skin or mucous membrane growths, a subset is implicated in severe health conditions, such as cervical, anal, vulvar, and vaginal cancers. Despite the established effectiveness of HPV vaccines in preventing cervical and anal carcinomas in particular, their therapeutic potential in addressing cutaneous diseases linked to diverse HPV strains remains an intriguing area of investigation. This narrative review critically examines the existing literature to assess the viability of HPV immunization as a therapeutic intervention for prevalent cutaneous conditions. These include genital and extragenital cutaneous warts, epidermodysplasia verruciformis, and keratinocyte carcinomas. The findings suggest a promising dual role for HPV vaccines in preventing and treating dermatologic conditions while emphasizing future research directions, including the immunization perspective against β-HPVs. Moreover, the presence of conflicting study outcomes underscores the imperative for larger-scale, randomized trials with well-matched control groups to validate the efficacy of HPV immunization in the dermatologic context. This review contributes valuable insights into the evolving landscape of HPV-vaccine applications in the field of dermatology.

show abstract

“…Conversely, numerous literature data suggest a possible therapeutic effect of HPV vaccination on existing HPV infection and HPV-induced benign proliferations, including AWs and cutaneous warts (CW) [ 47 , 48 , 49 , 50 , 51 , 52 ]. Regarding AWs, only Couselo Rodriguez treated a child with Gardasil-9, obtaining partial remission [ 53 ]. In adult AWs, the administration of the HPV vaccine achieved remission in 3 out of 3 patients, as reported by Dianzani, 6 of 10 patients, as reported by Choi, 1 of 1, as reported by Lee, 2 of 5, as reported by Bossart, and 1 of 1, as reported by Moscato [ 54 , 55 , 56 , 57 , 58 ].…”

Section: Resultsmentioning

confidence: 99%

Treatment of Pediatric Anogenital Warts in the Era of HPV-Vaccine: A Literature Review

Herzum

Ciccarese

Occella

et al. 2023

JCM

View full text Add to dashboard Cite

Anogenital warts (AWs) represent a therapeutic challenge, especially in infants, due to sensitive skin and frequent disease recurrence. Though the initial wait-and-see approach is often adopted in asymptomatic immunocompetent children, with spontaneous clearing in almost 90% of cases within two years, persistent or symptomatic lesions can be reasonably treated. However, few studies have been conducted on children. Consequently, most treatments on patients under age 12 are not approved by the Food and Drug Administration. Herein, we review possible therapies for pediatric use in AW and report an illustrative case of a two-year-old boy with atopic skin and symptomatic, persistent AWs who was successfully treated with topical podophyllotoxin, without adverse effects or recurrence. Among available therapies for AWs, topical therapies, such as immunomodulating-agents (topical imiquimod 5% and 3.75% cream, sinecatechins 15% ointment) and cytotoxic agents (podophyllotoxin and cidofovir) are considered manageable in children because of their low aggressiveness. In particular, podofillotoxin gel 5% and imiquimod 5% cream have been reported to be safe and efficacious in children. Currently, HPV vaccination is not recommended as a treatment for established HPV infection and AWs, yet a possible therapeutic role of HPV vaccination was recently suggested in the literature and deserves mention.

show abstract

Clearance of genital warts in a pediatric patient following administration of the nonavalent human papillomavirus vaccine

Cited by 4 publications

References 5 publications

Efficacy of Human Papillomavirus Vaccines for Recalcitrant Anogenital and Oral Warts

Efficacy of Human Papillomavirus Vaccines for Recalcitrant Anogenital and Oral Warts

Unveiling the Therapeutic Horizon: HPV Vaccines and Their Impact on Cutaneous Diseases—A Comprehensive Review

Treatment of Pediatric Anogenital Warts in the Era of HPV-Vaccine: A Literature Review

Contact Info

Product

Resources

About